| Hazard Information | Back Directory | [Description]
UR-3216, a prodrug, is a novel, selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 is the very tight binding of its active metabolite to platelets (Ki for resting platelets is < 1 nM). UR-2992, the active form of UR-3216, binds to platelets for a long period of time, while the unbound drug is rapidly cleared. UR-3216 is a promising, orally active GPIIb/IIIa antagonist for the treatment of cardiovascular diseases. | [Uses]
UR-3216 is a selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 has the potential for cardiovascular diseases research[1]. | [References]
[1] K Baba, et al. UR-3216: a manageable oral GPIIb/IIIa antagonist. Cardiovasc Drug Rev. 2001 Spring;19(1):25-40. DOI:10.1111/j.1527-3466.2001.tb00181.x |
|
|